Testimonies from our Partners

Partnership with Bio-venture



Collaboration started on November 23, 2021

“We are so happy to be partnering with Astellas, a world leader in developing gene therapies. Dyno and Astellas each bring unique strengths to this collaboration, together enabling more rapid creation of new therapies for patients with great unmet need. This partnership demonstrates the flexibility of Dyno’s platform to precisely design the delivery properties of gene therapy vectors towards multi-organ and disease-specific profiles, applying the scientific insights we are rapidly learning across all our partnered and internal vector engineering programs using CapsidMap.”

Eric D. Kelsic, Ph.D.
Dyno’s CEO and Co-founder


Collaboration started on June 14, 2023

“We are excited to enter into this strategic collaboration with Astellas using our novel E3 ligands which we discovered in-house. We are looking forward to working with Astellas to advance more targeted protein degraders into clinical development."

Ying Luo, Ph.D. 
President and CEO at Cullgen

CytomX Thrapeutics

Collaboration started on March 23, 2020

”We are excited about the use of our technology to assist Astellas in unlocking the potential of T-cell engagers (TCE) in the treatment of solid tumors, building on the growing proof of concept we have established for our platform. This collaboration with Astellas leverages CytomX’s deep expertise in targeting multiple antibody modalities to the tumor microenvironment. We have achieved two clinical candidate nomination since the start of this collaboration. Such continued momentum toward the potential future IND for the first PROBODY® TCE clinical candidate highlights the benefits of our strategy to create value through both wholly-owned and partnered programs.”

Sean A. McCarthy, D.Phil.
Chief Executive Officer and Chairman



Acquired on December 26, 2019

“Astellas has a powerful vision to develop off-the-shelf cellular therapies to greatly improve access and deliver to cancer patients the best possible outcomes. Xyphos is truly a part of this shared vision – something the team is reminded of daily as we work with other research divisions throughout the organization to solve pieces of this very complex puzzle and as the organization continuously seeks opportunities to engage in external partnerships to accelerate the realization of this vision. The dedication of the leadership teams, the drive of the scientists, and the quality of the support provided by all the groups that nurture a therapy’s journey from early research to patient outcomes has been inspirational. Xyphos is privileged to be part of Astellas’ Primary Focus Immuno-Oncology vision.”

Kaman Kim, Ph.D.
Director of Research, Xyphos